# Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers

> **NCT01371006** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 29 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** low dose
- **DRUG:** normal dose
- **DRUG:** low dose

## Key facts

- **NCT ID:** NCT01371006
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-09
- **Final completion:** —
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2015-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01371006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01371006, "Evaluation of the Effect of Multiple Dosing With BI 201335 on CYP2B6 Metabolism and Effect of Multiple Dosing With Efavirenz on the Steady-state Pharmacokinetics of BI 201335 and on CYP3A4/5 Metabolism in Healthy Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01371006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*